Drug intelligence / Profile preview

AR01

Development stage: Unknown
Lead developer: Aardvark Therapeutics
Modality: Small Molecules, Drug Delivery Systems
Administration: Otic

Overview

AR01 is an investigational medicated ear drop formulation being studied for the relief of pain in acute otitis media (middle ear infection) in children. In a clinical trial, children aged 2 months to less than 19 years with middle ear infections received either AR01 or placebo (glycerin) ear drops to assess pain reduction. The specific active ingredients, mechanism of action, and developer details are not provided in the available sources. The drug is administered as an otic solution and is intended for short-term use (up to 4 days) for symptomatic relief of ear pain associated with acute otitis media[3].

Beyond the preview

Go deeper on AR01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR01.

Explore the full profile